Editas Medicine Names Emma Reeve to Board of Directors
CAMBRIDGE, Mass.,
“I am very pleased to welcome Emma to our Board of Directors. She is an accomplished biopharmaceutical executive with extensive financial and operational experience plus significant achievements in fundraising activities. Her work has led to several business transactions and collaborations that brought resources to companies to continue development of important medicines,” said
“I am elated to join Editas Medicine’s Board of Directors as the company makes strides in the clinic and continues to advance its pipeline and unparalleled technology. I look forward to being part of this exceptional Board and helping Editas in its mission to develop and advance transformative medicines,” said
About Editas Medicine
As a leading genome editing company,
Forward-Looking Statements
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company’s product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K, which is on file with the
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/edda5898-3104-4da9-a550-2ef539ccdbbf
Contacts: MediaCristi Barnett (617) 401-0113 cristi.barnett@editasmed.com InvestorsRon Moldaver (617) 401-9052 ir@editasmed.com
Source: Editas Medicine, Inc.